Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA

Executive Summary

Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.


Related Content

US FDA Developing Database Of Medical Review Decisions, Gottlieb Tells Congress
At US Generic Association Annual Meeting, Worries About Sustainability
Trump's Budget Surprise: FDA Gains 13% Increase
US FDA Looks To Proactively Update Old Generic Drug Labels Under Pilot
FDA Ends ANDA 'Reviews' To Streamline Approval Process
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
ANDA Refuse-to-Receive Challenges Become More Common – And More Successful
FDA Flexible With Accelerated Approval Evidence, Analysis Finds
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts